---
title: "Daiichi Sankyo Company: Oncology-driven revenue growth and FX gains lifted results, but profit fell on higher costs"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294452336.md"
description: "Revenue grew 21.1% year-over-year, led by oncology product sales and FX gains, while core operating profit rose 6.2%. Full-year revenue guidance was raised, but profit attributable to owners declined 19.7% due to higher taxes and expenses. Major oncology approvals and a phased divestiture of the healthcare unit were key developments.Original document: Daiichi Sankyo Company, Limited [4568] Interim report — Jul. 31 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-31T04:02:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294452336.md)
  - [en](https://longbridge.com/en/news/294452336.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294452336.md)
generator: "portal-rs"
---

# Daiichi Sankyo Company: Oncology-driven revenue growth and FX gains lifted results, but profit fell on higher costs

Revenue grew 21.1% year-over-year, led by oncology product sales and FX gains, while core operating profit rose 6.2%. Full-year revenue guidance was raised, but profit attributable to owners declined 19.7% due to higher taxes and expenses. Major oncology approvals and a phased divestiture of the healthcare unit were key developments.

Original document: Daiichi Sankyo Company, Limited \[4568\] Interim report — Jul. 31 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [DSNKY.US](https://longbridge.com/en/quote/DSNKY.US.md)
- [4568.JP](https://longbridge.com/en/quote/4568.JP.md)

## Related News & Research

- [Daiichi promotes Ken Keller to lead new commercialization unit](https://longbridge.com/en/news/296867871.md)
- [Zalando says AI-driven content must keep products accurately represented, with human checks in place](https://longbridge.com/en/news/296870779.md)
- [Echo IQ Issues New Shares Following Option Exercise](https://longbridge.com/en/news/296588483.md)
- [RenovoRx highlights Phase III TIGeR-PaC sub-study showing 51% tumor-site gemcitabine extraction with TAMP delivery](https://longbridge.com/en/news/296914646.md)
- [Carvolix, Truffle Capital launch SAF-MD Saudi-French medical cooperation program](https://longbridge.com/en/news/296812494.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**